Literature DB >> 17698706

Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.

Maria Pia Amato1, Emilio Portaccio, Benedetta Goretti, Valentina Zipoli, Marco Battaglini, Maria Letizia Bartolozzi, Maria Laura Stromillo, Leonello Guidi, Gianfranco Siracusa, Sandro Sorbi, Antonio Federico, Nicola De Stefano.   

Abstract

BACKGROUND: We previously reported selective decreases of neocortical volumes in patients with early relapsing-remitting (RR) multiple sclerosis (MS) with mild cognitive impairment, with a good correlation between cortical volumes and cognitive measures.
OBJECTIVE: To assess the relevance of gray matter changes over time to changes in cognition in RRMS.
DESIGN: A longitudinal survey after 2.5 years. Each patient underwent a magnetic resonance imaging (MRI) protocol identical to that performed at baseline; cognitive performance was reassessed with the Rao Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis.
SETTING: Two university MS clinics. PATIENTS: Of 41 patients with RRMS who participated in the original cross-sectional study, 28 were available for the follow-up evaluation (18 women; mean +/- SD age, 37.1 +/- 8.9 years; mean +/- SD MS duration, 7.3 +/- 2.9 years; mean +/- SD Expanded Disability Status Scale score, 1.8 +/- 1.5). MAIN OUTCOME MEASURES: We measured the percentage of brain volume changes, normalized cortical volume (NCV) changes, and normalized deep gray matter volume changes on conventional T1-weighted MRIs and changes in lesion load on T2-weighted MRIs. The number of tests failed on the Rao Brief Repeatable Battery were used to classify the patients as cognitively deteriorating or stable or improving.
RESULTS: We identified 12 of 28 cognitively deteriorating and 16 of 28 stable or improving patients. These subgroups did not differ in the mean +/- SD percentage of brain volume changes (-2.1% +/- 1.2% vs -1.3% +/- 1.3%; P = .11), normalized deep gray matter volume changes (-2.1 +/- 2.8 mL vs -0.6 +/- 3.1 mL; P = .60), and changes in lesion load on T2-weighted MRIs (1.9 +/- 2.6 mL vs 1.6 +/- 2.3 mL; P = .73). However, NCV changes were significantly higher in deteriorating than in stable or improving patients (-43.0 +/- 18.9 mL vs -17.8 +/- 26.6 mL; P = .007). In deteriorating patients, NCV changes were correlated with performance in a verbal fluency test (r = 0.73; P < .001). In a regression model, only NCV changes were significantly associated with deteriorating cognitive performance (odds ratio, 0.8; 95% confidence interval, 0.7-0.9).
CONCLUSION: Progressive neocortical gray matter loss is relevant to MS-associated cognitive impairment and may represent a sensitive marker of deteriorating cognitive performance in RRMS.

Entities:  

Mesh:

Year:  2007        PMID: 17698706     DOI: 10.1001/archneur.64.8.1157

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  67 in total

1.  Brain networks disconnection in early multiple sclerosis cognitive deficits: an anatomofunctional study.

Authors:  Céline Louapre; Vincent Perlbarg; Daniel García-Lorenzo; Marika Urbanski; Habib Benali; Rana Assouad; Damien Galanaud; Léorah Freeman; Benedetta Bodini; Caroline Papeix; Ayman Tourbah; Catherine Lubetzki; Stéphane Lehéricy; Bruno Stankoff
Journal:  Hum Brain Mapp       Date:  2014-03-31       Impact factor: 5.038

2.  Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily.

Authors:  Francesco Patti; Alessandra Nicoletti; Silvia Messina; Elisa Bruno; Salvatore Lo Fermo; Graziella Quattrocchi; Clara Grazia Chisari; Davide Maimone; Sabina Cilia; Mario Zappia
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

3.  Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.

Authors:  Tomas Uher; Jana Blahova-Dusankova; Dana Horakova; Niels Bergsland; Michaela Tyblova; Ralph H B Benedict; Tomas Kalincik; Deepa P Ramasamy; Zdenek Seidl; Jesper Hagermeier; Manuela Vaneckova; Jan Krasensky; Eva Havrdova; Robert Zivadinov
Journal:  J Neurol       Date:  2014-06-22       Impact factor: 4.849

4.  Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis.

Authors:  Sonia Batista; Robert Zivadinov; Marietta Hoogs; Niels Bergsland; Mari Heininen-Brown; Michael G Dwyer; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  J Neurol       Date:  2011-07-01       Impact factor: 4.849

5.  Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patients.

Authors:  Seyed-Parsa Hojjat; Charles Grady Cantrell; Rita Vitorino; Anthony Feinstein; Zahra Shirzadi; Bradley J MacIntosh; David E Crane; Lying Zhang; Sarah A Morrow; Liesly Lee; Paul O'Connor; Timothy J Carroll; Richard I Aviv
Journal:  Mult Scler       Date:  2016-01-11       Impact factor: 6.312

6.  MRI predictors of cognitive outcome in early multiple sclerosis.

Authors:  M S A Deloire; A Ruet; D Hamel; M Bonnet; V Dousset; B Brochet
Journal:  Neurology       Date:  2011-03-29       Impact factor: 9.910

Review 7.  Clinical relevance of brain volume measures in multiple sclerosis.

Authors:  Nicola De Stefano; Laura Airas; Nikolaos Grigoriadis; Heinrich P Mattle; Jonathan O'Riordan; Celia Oreja-Guevara; Finn Sellebjerg; Bruno Stankoff; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

8.  Cerebellum and cognition in multiple sclerosis: the fall status matters.

Authors:  Alon Kalron; Gilles Allali; Anat Achiron
Journal:  J Neurol       Date:  2018-02-02       Impact factor: 4.849

9.  Short-latency afferent inhibition predicts verbal memory performance in patients with multiple sclerosis.

Authors:  Laura Cucurachi; Paolo Immovilli; Franco Granella; Giovanni Pavesi; Luigi Cattaneo
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

Review 10.  Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

Authors:  Blandine Grassiot; Béatrice Desgranges; Francis Eustache; Gilles Defer
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.